论文部分内容阅读
目的探讨胰激肽原酶注射液早期应用对糖尿病肾病的转归。方法选择符合纳入标准的糖尿病肾病患者,分为治疗组和观察组,观察24h尿微量白蛋白变化。结果观察组经用药24h后尿微量白蛋白明显下降,与治疗组相比差异有统计学意义。结论胰激肽原酶注射液能显著减少糖尿病肾病早期患者的24h尿微量白蛋白,减缓糖尿病肾病的进展。
Objective To investigate the early application of pancreatic kallikrein injection on diabetic nephropathy. Methods Patients with diabetic nephropathy who met the inclusion criteria were divided into treatment group and observation group, and the changes of urinary albumin after 24h were observed. Results The microalbuminuria of observation group decreased obviously after treated with drug for 24 hours, the difference was statistically significant compared with the treatment group. Conclusion pancreatic kallikrein injection can significantly reduce the early diabetic nephropathy 24h urine microalbumin, slow down the progress of diabetic nephropathy.